Literature DB >> 25011528

Imaging the role of amyloid in PD dementia and dementia with Lewy bodies.

Stephen N Gomperts1.   

Abstract

Cognitive impairment and dementia are significant sequelae of Parkinson disease (PD) and comprise a key feature of dementia with Lewy bodies (DLB), a disease with similar clinical and neuropathological features. Multiple independent causes have been implicated in PD dementia (PDD) and DLB, among them the accumulation of β-amyloid, a neuropathological hallmark of Alzheimer disease. Over the last decade, PET imaging has emerged as a viable method to measure amyloid burden in the human brain and relate it to neurodegenerative diseases. This article reviews what amyloid imaging has taught us about PDD and DLB. Current data suggest that brain amyloid deposition tends to be more marked in DLB, yet contributes to cognitive impairment in both DLB and PD. These results are broadly consistent with neuropathology and CSF studies. β-Amyloid may interact synergistically with other pathological processes in PD and DLB to contribute to cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25011528     DOI: 10.1007/s11910-014-0472-6

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  118 in total

1.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

Authors:  Nobuyuki Okamura; Shozo Furumoto; Michelle T Fodero-Tavoletti; Rachel S Mulligan; Ryuichi Harada; Paul Yates; Svetlana Pejoska; Yukitsuka Kudo; Colin L Masters; Kazuhiko Yanai; Christopher C Rowe; Victor L Villemagne
Journal:  Brain       Date:  2014-03-27       Impact factor: 13.501

2.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  Predictors of survival in dementia with lewy bodies and Parkinson dementia.

Authors:  Kurt A Jellinger; Gregor K Wenning; Klaus Seppi
Journal:  Neurodegener Dis       Date:  2007-10-09       Impact factor: 2.977

4.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

Review 5.  Biomarkers in dementia with Lewy bodies: a review.

Authors:  Namrta Sinha; Michael Firbank; John T O'Brien
Journal:  Int J Geriatr Psychiatry       Date:  2011-07-01       Impact factor: 3.485

6.  β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.

Authors:  Hitoshi Shimada; Hitoshi Shinotoh; Shigeki Hirano; Michie Miyoshi; Koichi Sato; Noriko Tanaka; Tsuneyoshi Ota; Kiyoshi Fukushi; Toshiaki Irie; Hiroshi Ito; Makoto Higuchi; Satoshi Kuwabara; Tetsuya Suhara
Journal:  Mov Disord       Date:  2012-12-05       Impact factor: 10.338

7.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

8.  In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

Authors:  Michelle T Fodero-Tavoletti; David P Smith; Catriona A McLean; Paul A Adlard; Kevin J Barnham; Lisa E Foster; Laura Leone; Keyla Perez; Mikhalina Cortés; Janetta G Culvenor; Qiao-Xin Li; Katrina M Laughton; Christopher C Rowe; Colin L Masters; Roberto Cappai; Victor L Villemagne
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

9.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Authors:  Sara Hall; Annika Öhrfelt; Radu Constantinescu; Ulf Andreasson; Yulia Surova; Frederick Bostrom; Christer Nilsson; Widner Håkan; Hilde Decraemer; Katarina Någga; Lennart Minthon; Elisabet Londos; Eugeen Vanmechelen; Björn Holmberg; Henrik Zetterberg; Kaj Blennow; Oskar Hansson
Journal:  Arch Neurol       Date:  2012-11

10.  PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.

Authors:  Andrew Siderowf; Michael J Pontecorvo; Holly A Shill; Mark A Mintun; Anupa Arora; Abhinay D Joshi; Ming Lu; Charles H Adler; Douglas Galasko; Carolyn Liebsack; Daniel M Skovronsky; Marwan N Sabbagh
Journal:  BMC Neurol       Date:  2014-04-09       Impact factor: 2.474

View more
  18 in total

1.  PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies.

Authors:  Stephen N Gomperts; Marta Marquie; Joseph J Locascio; Stephen Bayer; Keith A Johnson; John H Growdon
Journal:  Neurodegener Dis       Date:  2015-12-08       Impact factor: 2.977

Review 2.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

3.  Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease.

Authors:  Julia Shirvan; Nathan Clement; Rong Ye; Samantha Katz; Aaron Schultz; Keith A Johnson; Teresa Gomez-Isla; Matthew Frosch; John H Growdon; Stephen N Gomperts
Journal:  Neurology       Date:  2019-06-26       Impact factor: 9.910

4.  Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.

Authors:  Inger van Steenoven; Dag Aarsland; Daniel Weintraub; Elisabet Londos; Frédéric Blanc; Wiesje M van der Flier; Charlotte E Teunissen; Brit Mollenhauer; Tormod Fladby; Milica G Kramberger; Laura Bonanni; Afina W Lemstra
Journal:  J Alzheimers Dis       Date:  2016-08-18       Impact factor: 4.472

Review 5.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

Review 6.  Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia.

Authors:  Stephen N Gomperts
Journal:  Continuum (Minneap Minn)       Date:  2016-04

7.  The relationship between amyloid deposition, neurodegeneration, and cognitive decline in dementia.

Authors:  Rik Vandenberghe
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

8.  Resting state in Parkinson's disease dementia and dementia with Lewy bodies: commonalities and differences.

Authors:  Luis R Peraza; Sean J Colloby; Michael J Firbank; G Shirmin Greasy; Ian G McKeith; Marcus Kaiser; John O'Brien; John-Paul Taylor
Journal:  Int J Geriatr Psychiatry       Date:  2015-08-13       Impact factor: 3.485

9.  Arguing against the proposed definition changes of PD.

Authors:  Bradley F Boeve; Dennis W Dickson; John E Duda; Tanis J Ferman; Douglas R Galasko; James E Galvin; Jennifer G Goldman; John H Growdon; Howard I Hurtig; Daniel I Kaufer; Kejal Kantarci; James B Leverenz; Carol F Lippa; Oscar L Lopez; Ian G McKeith; Andrew B Singleton; Angela Taylor; Debby Tsuang; Daniel Weintraub; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2016-08-05       Impact factor: 10.338

10.  Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.

Authors:  Stephen N Gomperts; Joseph J Locascio; Sara J Makaretz; Aaron Schultz; Christina Caso; Neil Vasdev; Reisa Sperling; John H Growdon; Bradford C Dickerson; Keith Johnson
Journal:  JAMA Neurol       Date:  2016-11-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.